Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [3] - The company's lead product is Ampligen (rintatolimod), a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator, showing broad spectrum activity in clinical trials [3] Upcoming Event - AIM will participate in the Corporate Connect Webinar Series hosted by Webull Financial on February 10-11, 2026 [1] - Thomas K. Equels, the CEO of AIM, will provide a corporate overview and business outlook, with a focus on the company's strategic emphasis on pancreatic cancer [1] - The presentation is scheduled for February 11, 2026, at 1:40 PM EST [1]

Core Insights - AIM ImmunoTech Inc. reported positive data from the ongoing Phase 2 clinical study of Ampligen combined with AstraZeneca's Imfinzi for treating metastatic pancreatic cancer, showing median survival of 19.7 months compared to 8.6 months with standard care [1][2] - The study aims to assess the clinical benefit rate, overall survival, progression-free survival, immune monitoring, and quality of life for patients [2][3] Group 1: Clinical Study Details - The DURIPANC study is an exploratory, open-label trial expected to enroll up to 25 subjects, with 18 patients already enrolled [3] - The study has shown promising results in progression-free survival and overall survival, with no significant toxicity reported, indicating a favorable safety profile [3][4] - The combination therapy appears to enhance the body's immune response, suggesting a coordinated activation of both innate and adaptive immune systems [5] Group 2: Market Potential and Intellectual Property - AIM holds a U.S. patent for Ampligen as an oncology treatment in combination with anti-PD-L1 therapies, extending protection until August 9, 2039 [7] - The company has received orphan drug designations in pancreatic cancer from both the U.S. and EU, providing market exclusivity post-commercial approval [7][8] - AIM believes that advancing Ampligen to Phase 3 clinical trials could present significant financial opportunities for the company and its shareholders [5][8]

西班牙巴塞罗那, Jan. 30, 2026 (GLOBE NEWSWIRE) -- AI 驱动型字幕与语言解决方案的全球领军企业 AI-Media 将亮相 ISE 2026，现场展示实时翻译、字幕生成与音频描述如何成为从现场活动、企业沟通到场馆与公共设施等专业视听环境中的核心功能。 随着受众语言背景日趋多元化以及手中对包容性沟通的期望持续提升，视听团队正面临全新挑战：必须确保无论是现场观众还是远程观众，都能获得无障碍、易理解且体验一致的传播效果。 在 ISE 2026，AI-Media 将展示其广播级 AI 技术如何应用于集成化视听工作流，以低延迟实现可扩展的实时语言支持与无障碍服务。 在 4L700 展位，AI-Media 将展示 LEXI Voice——一款 AI 驱动的实时语音翻译解决方案，能够以自然流畅且延迟极低的输出效果将语音翻译成任何语言。 LEXI Voice 专为现场活动与广播环境设计，助力活动制作方、内容所有者及视听集成商在不增加制作流程复杂度的前提下实现多语言沟通。 除 LEXI Voice 外，AI-Media 还将演示其实时 AI 字幕解决方案 LEXI Text，以及旨在提供无障碍 ...

As filed with the Securities and Exchange Commission on January 29, 2026 Registration No. 333-292085 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AIM ImmunoTech Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 52-0845822 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Num ...

BARCELONA, Spain, Jan. 29, 2026 (GLOBE NEWSWIRE) -- AI-Media, a global leader in AI-powered subtitling and language solutions, will be at ISE 2026 to demonstrate how real-time translation, captioning, and audio description are becoming essential capabilities across professional AV environments - from live events and corporate communications to venues and public installations. As audiences become increasingly multilingual and expectations for inclusive communication continue to rise, AV teams are being chall ...

Company Overview - AIM ImmunoTech Inc. is a member of the Medical sector, which includes 931 individual stocks and currently holds a Zacks Sector Rank of 9 [2] - AIM ImmunoTech Inc. belongs to the Medical - Drugs industry, which consists of 141 individual stocks and is currently ranked 96 in the Zacks Industry Rank [5] Performance Analysis - AIM ImmunoTech Inc. has gained about 7.1% year-to-date, which matches the average return of Medical companies [4] - The Zacks Consensus Estimate for AIM's full-year earnings has increased by 3.8% over the past quarter, indicating improved analyst sentiment and a stronger earnings outlook [4] - In comparison, Cullinan Therapeutics, another Medical stock, has outperformed the sector with a year-to-date increase of 19.2% [4] Industry Comparison - The Medical - Drugs industry, to which AIM belongs, has seen an average gain of 3.5% this year, indicating that AIM is performing better than its industry peers [5] - Cullinan Therapeutics is part of the Medical - Biomedical and Genetics industry, which has moved up by 22.9% so far this year, and is currently ranked 94 [6]

OCALA, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, announced today changes to the previously announced key dates relating to its proposed rights offering (the “Rights Offering”). Except as expressly amended herein, the terms of the Rights Offering remain unchanged. Assumin ...

Core Viewpoint - AIM ImmunoTech Inc. is conducting a proposed rights offering to raise gross proceeds of $12 million, which will be used for general corporate purposes, including clinical trial expenses and debt repayment [1][5]. Rights Offering Details - The rights offering will provide one non-transferable subscription right for each share of common stock and certain options and warrants held as of the record date of February 4, 2026 [2]. - Each subscription right allows the purchase of one unit at a subscription price of $1,000, with each unit consisting of one share of Series G Convertible Preferred Stock and warrants to purchase 1,492 shares of common stock [2]. - The subscription rights are non-transferable and can be exercised from February 5, 2026, to February 23, 2026, unless extended by the company [3][6]. Leadership Participation - Certain members of AIM's leadership, including CEO Thomas K. Equels, have indicated a non-binding intention to participate in the rights offering [4]. Use of Proceeds - The net proceeds from the rights offering will be allocated for clinical trial expenses related to Phase 2/3 pancreatic cancer trials and to repay certain existing debt obligations [5]. Important Dates - Key dates for the rights offering include: - February 3, 2026: Ownership Day for stockholders of record - February 4, 2026: Record Date - February 5, 2026: Subscription Period Begins - February 23, 2026: Subscription Period Ends [7]. Information Distribution - Broadridge Corporate Issuer Solutions, LLC will mail rights certificates and a prospectus to holders of record starting on or about February 5, 2026 [8].

As filed with the Securities and Exchange Commission on January 23, 2026 Registration No. 333-292085 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 AIM ImmunoTech Inc. (I.R.S. Employer Identification Number) 2117 SW Highway 484 Ocala FL 34473 (352) 448-7797 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Thomas K. Equels Chief Executive Officer AIM ImmunoTech Inc. 2117 SW Highway 484 Oc ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. AIM ImmunoTech Inc. (AIM) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.AIM ImmunoTech Inc. is one of 932 individual stocks in the Medical sector. Collectively, these com ...